Decade-Long Prodrome on Neuroimaging: Unique Insight into Probable Corticobasal Degeneration.
Tai XY. et al, (2025), Mov Disord
Working memory filtering at encoding and maintenance in healthy ageing, Alzheimer's and Parkinson's disease.
Toniolo S. et al, (2025), Sci Rep, 15
Treatment Selection and Prioritization for the EJS ACT-PD MAMS Trial Platform.
Gonzalez-Robles C. et al, (2025), Mov Disord
Neuronally Derived Extracellular Vesicle α-Synuclein as a Serum Biomarker for Individuals at Risk of Developing Parkinson Disease.
Yan S. et al, (2024), JAMA Neurol, 81, 59 - 68
Detailed Analysis of ITPR1 Missense Variants Guides Diagnostics and Therapeutic Design.
Tolonen JP. et al, (2023), Mov Disord
Heterozygous UCHL1 loss-of-function variants cause a neurodegenerative disorder with spasticity, ataxia, neuropathy, and optic atrophy.
Park J. et al, (2023), Genet Med, 25
Normal and pathogenic variation of RFC1 repeat expansions: implications for clinical diagnosis.
Dominik N. et al, (2023), Brain
Towards a multi-arm multi-stage platform trial of disease modifying approaches in Parkinson's disease.
Foltynie T. et al, (2023), Brain, 146, 2717 - 2722
The Phenotypic Continuum of ATP1A3-Related Disorders.
Vezyroglou A. et al, (2022), Neurology, 99, e1511 - e1526
Initiation and progression of α-synuclein pathology in Parkinson's disease.
Tofaris GK., (2022), Cell Mol Life Sci, 79
Longitudinal changes of early motor and cognitive symptoms in progressive supranuclear palsy: the OxQUIP study.
Pereira MF. et al, (2022), BMJ Neurol Open, 4
Treatment Selection in Multi-Arm Multi-Stage Clinical Trials in Parkinson Disease: The Search for the Ideal Neuroprotective Drug
Gonzalez-Robles C. et al, (2022), MOVEMENT DISORDERS, 37, S329 - S329
Multiplexed Profiling of Extracellular Vesicles for Biomarker Development.
Jiang C. et al, (2021), Nanomicro Lett, 14
Validation of α-Synuclein in L1CAM-Immunocaptured Exosomes as a Biomarker for the Stratification of Parkinsonian Syndromes.
Jiang C. et al, (2021), Mov Disord, 36, 2663 - 2669
Phenotypic manifestation of α-synuclein strains derived from Parkinson's disease and multiple system atrophy in human dopaminergic neurons.
Tanudjojo B. et al, (2021), Nat Commun, 12
Facile Impedimetric Analysis of Neuronal Exosome Markers in Parkinson's Disease Diagnostics.
Fu Y. et al, (2020), Anal Chem, 92, 13647 - 13651
Serum neuronal exosomes predict and differentiate Parkinson's disease from atypical parkinsonism.
Jiang C. et al, (2020), J Neurol Neurosurg Psychiatry, 91, 720 - 729
How is alpha-synuclein cleared from the cell?
Stefanis L. et al, (2019), J Neurochem, 150, 577 - 590